Related Experiment Videos
Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations
1Department of Infectious Diseases, University Hospital, Leiden, The Netherlands.
Summary
Pneumococcal polysaccharide vaccines are effective in many at-risk groups but not infants or immunocompromised individuals. Further development of conjugate vaccines is needed for broader protection against Streptococcus pneumoniae infections.
Area of Science:
- Infectious Diseases
- Vaccinology
- Immunology
Background:
- Streptococcus pneumoniae causes significant community-acquired pneumonia, meningitis, and otitis media.
- High mortality persists for pneumococcal infections, especially those with bacteremia, despite available treatments.
- Vaccination efforts against pneumococcal disease began over a century ago.
Purpose of the Study:
- To review the efficacy of existing pneumococcal vaccines.
- To identify populations inadequately protected by current vaccines.
- To advocate for the development of more immunogenic vaccines.
Main Methods:
- Review of historical and current pneumococcal vaccination strategies.
- Analysis of serological studies on immune response to pneumococcal antigens.
- Evaluation of vaccine efficacy in various demographic and clinical groups.
Main Results:
- Purified pneumococcal polysaccharide vaccines are effective in young adults and certain at-risk groups (elderly, sickle cell anemia, post-splenectomy).
- Vaccine efficacy is limited in infants and severely immunocompromised patients due to impaired antibody response.
- Current vaccines do not provide adequate protection for all populations at risk.
Conclusions:
- Conjugate vaccines linking pneumococcal polysaccharides to protein carriers are necessary for improved immunogenicity.
- Further research and development are crucial to protect vulnerable populations.
- Maximizing immunization opportunities in responsive at-risk groups is essential.